116 related articles for article (PubMed ID: 23965952)
21. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer.
Cao J; Song Y; Bi N; Shen J; Liu W; Fan J; Sun G; Tong T; He J; Shi Y; Zhang X; Lu N; He Y; Zhang H; Ma K; Luo X; Lv L; Deng H; Cheng J; Zhu J; Wang L; Zhan Q
Cancer Res; 2013 Jun; 73(11):3326-35. PubMed ID: 23592755
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer.
Rehfeld N; Geddert H; Atamna A; Gabbert HE; Steidl U; Fenk R; Kronenwett R; Haas R; Rohr UP
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2232-8. PubMed ID: 17119051
[TBL] [Abstract][Full Text] [Related]
25. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
26. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
27. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
28. Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.
Sun L; Sui L; Cong X; Ma K; Ma X; Huang Y; Fan C; Fu X; Ma K
Cancer Genet; 2014; 207(7-8):291-8. PubMed ID: 25242236
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung.
LaPoint RJ; Bourne PA; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):401-6. PubMed ID: 18091382
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological significance of expression of c-kit protein in neuroendocrine lung carcinoma].
Zhao P; Hou N; Shao Y; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(22):1526-9. PubMed ID: 16179109
[TBL] [Abstract][Full Text] [Related]
31. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations.
Aubry MC; Heinrich MC; Molina J; Lewis JE; Yang P; Cassivi SD; Corless CL
Cancer; 2007 Dec; 110(11):2507-10. PubMed ID: 17932891
[TBL] [Abstract][Full Text] [Related]
32. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
33. [A new strategy for treating small cell lung cancer].
Ueda R; Takashi T
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Dec; 34 Suppl():111-4. PubMed ID: 9216197
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
35. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
37. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.
Blackhall FH; Pintilie M; Michael M; Leighl N; Feld R; Tsao MS; Shepherd FA
Clin Cancer Res; 2003 Jun; 9(6):2241-7. PubMed ID: 12796392
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of small cell lung cancer in a Japanese cohort.
Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
[TBL] [Abstract][Full Text] [Related]
39. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal GW; Hines SJ; Organ CP
Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594
[TBL] [Abstract][Full Text] [Related]
40. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
Chang YL; Wu CT; Shih JY; Lee YC
Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
